| Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review CECC Group, L Ghosn, A Chaimani, T Evrenoglou, M Davidson, C Graña, ... Cochrane database of systematic reviews 2021 (3), 2021 | 211 | 2021 |
| Efficacy and safety of COVID‐19 vaccines CECC Group, C Graña, L Ghosn, T Evrenoglou, A Jarde, S Minozzi, ... Cochrane Database of Systematic Reviews 2023 (3), 2022 | 203* | 2022 |
| Interleukin‐1 blocking agents for treating COVID‐19 CECC Group, M Davidson, S Menon, A Chaimani, T Evrenoglou, L Ghosn, ... Cochrane Database of Systematic Reviews 2022 (1), 2022 | 43* | 2022 |
| Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials P Riviere, P Ripoll, J Barnier, R Vuillemot, G Ferrand, S Cohen-Boulakia, ... Journal of Clinical Epidemiology 130, 107-116, 2021 | 26 | 2021 |
| Meta‐analysis results do not reflect the real safety of biologics in psoriasis S Afach, A Chaimani, T Evrenoglou, L Penso, E Brouste, E Sbidian, ... British Journal of Dermatology 184 (3), 415-424, 2021 | 25 | 2021 |
| Illness perceptions and quality of life in families with child with atopic dermatitis V Siafaka, A Zioga, T Evrenoglou, D Mavridis, S Tsabouri Allergologia et Immunopathologia 48 (6), 603-611, 2020 | 19 | 2020 |
| Efficacy and safety of COVID-19 vaccines., 2022, 12, p C Graña, L Ghosn, T Evrenoglou, A Jarde, S Minozzi, H Bergman, ... CD015477. DOI: https://doi. org/10.1002/14651858. CD015477, 0 | 9 | |
| metaCOVID: A web‐application for living meta‐analyses of COVID‐19 trials T Evrenoglou, I Boutron, G Seitidis, L Ghosn, A Chaimani Research Synthesis Methods 14 (3), 479-488, 2023 | 4* | 2023 |
| Network meta‐analysis of rare events using penalized likelihood regression T Evrenoglou, IR White, S Afach, D Mavridis, A Chaimani Statistics in Medicine 41 (26), 5203-5219, 2022 | 4 | 2022 |
| Most randomized controlled trials for psoriasis used placebo comparators despite the availability of effective treatments S Afach, T Evrenoglou, N Oubaya, L Le Cleach, E Sbidian Journal of Clinical Epidemiology 133, 72-79, 2021 | 2 | 2021 |
| No evidence of important difference in summary treatment effects between COVID-19 preprints and peer-reviewed publications: a meta-epidemiological study M Davidson, T Evrenoglou, C Graña, A Chaimani, I Boutron Journal of Clinical Epidemiology 162, 90-97, 2023 | 1 | 2023 |
| Introduction to Meta-Analysis T Evrenoglou, S Metelli, A Chaimani In Piantadosi S., Meinert C.L. (eds) Principles and Practice of Clinical Trials, 2021 | 1 | 2021 |
| Comparison of effect estimates between preprints and peer-reviewed journal articles of COVID-19 trials M Davidson, T Evrenoglou, C Graña, A Chaimani, I Boutron BMC Medical Research Methodology 24 (1), 9, 2024 | | 2024 |
| Sharing information across patient subgroups to draw conclusions from sparse treatment networks T Evrenoglou, S Metelli, JS Thomas, S Siafis, RM Turner, S Leucht, ... arXiv preprint arXiv:2301.09442, 2023 | | 2023 |
| Gestion des données éparses dans les méta-analyses en réseau T Evrenoglou | | 2022 |
| Utilisation du groupe placebo dans les essais contrôlés randomisés sur le psoriasis S Afach, A Chaimani, T Evrenoglou, N Oubaya, L Le Cleach, É Sbidian Annales de Dermatologie et de Vénéréologie 147 (12), A247, 2020 | | 2020 |
| Stratification according to disease severity can better reveal the relative effectiveness of treatments for acne vulgaris T Evrenoglou Lancet 380, 2163-96, 2012 | | 2012 |
Anna ChaimaniInserm, Université Paris CitéVerified email at parisdescartes.fr
